Plasma Exchange and IVIG for Autoimmune Neurological Disease

Plasma exchange (plasmapheresis) and intravenous immunoglobulin (IVIG) are two immune-modulating therapies used to treat a broad class of autoimmune neurological disorders in which the body's immune system attacks nervous system tissue. Both treatments work by altering the burden of pathogenic antibodies or immune mediators in circulation, but they achieve this through distinct mechanisms and carry different risk profiles. Understanding how each therapy works, when each is appropriate, and how clinical decision-making distinguishes between them is essential context for patients, caregivers, and students of neurology and its subspecialties.

Definition and scope

Plasma exchange (PLEX) is an extracorporeal procedure in which a patient's blood is drawn, separated by centrifugation or membrane filtration, and the plasma fraction — which carries antibodies, complement proteins, and other soluble immune factors — is removed and replaced with a substitute fluid such as albumin or fresh frozen plasma. Intravenous immunoglobulin (IVIG) is a pooled preparation of immunoglobulin G (IgG) antibodies derived from thousands of human donors, administered by intravenous infusion to modulate immune function through passive mechanisms.

Both therapies fall under the category of immunotherapy used in acute and chronic autoimmune neurological disease. The U.S. Food and Drug Administration (FDA) has granted formal approval for IVIG in specific indications, including myasthenia gravis and related neuromuscular disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy. PLEX is not administered as a drug and therefore is not subject to the same FDA drug-approval pathway; instead, its use is governed by institutional protocols and American Society for Apheresis (ASFA) guidelines, which classify indications by evidence strength from Category I (first-line therapy with established efficacy) through Category IV (insufficient evidence or harm demonstrated). The ASFA Guidelines on the Use of Therapeutic Apheresis in Clinical Practice (updated periodically, most recently as the 8th Special Issue in the journal Journal of Clinical Apheresis) remain the primary reference standard for PLEX indication classification.

The broader regulatory and insurance coverage landscape governing these therapies is addressed in the regulatory context for neurological treatments resource.

How it works

Plasma exchange — mechanism

PLEX reduces circulating pathogenic antibodies directly and rapidly. In autoimmune neurological diseases, antibodies directed against neural targets — such as acetylcholine receptors in myasthenia gravis or voltage-gated calcium channels in Lambert-Eaton syndrome — disrupt neuromuscular or central nervous system function. A standard PLEX course typically involves 5 to 7 exchanges performed over 10 to 14 days, each exchange processing approximately 1.0 to 1.5 plasma volumes. Because antibody levels rebound as the immune system continues production, PLEX is primarily a bridge therapy used to achieve rapid stabilization rather than long-term suppression.

IVIG — mechanism

IVIG exerts its effects through multiple simultaneous pathways. The pooled IgG saturates Fc receptors on macrophages and other immune effector cells, reducing their capacity to destroy antibody-coated targets. IVIG also neutralizes circulating autoantibodies via anti-idiotypic binding, modulates complement activation, and shifts the balance of regulatory T-cell activity. A standard acute dosing regimen is 2 g/kg total dose, administered over 2 to 5 consecutive days. Maintenance dosing for chronic conditions such as CIDP is typically 1 g/kg every 3 to 4 weeks, though individualization is standard practice based on response and tolerability.

The relevant overview of the neurological authority resource provides additional context on how these therapies fit within the broader landscape of neurological treatment approaches.

Common scenarios

Autoimmune neurological conditions in which PLEX or IVIG are routinely employed include the following:

  1. Myasthenia gravis (MG) exacerbation or myasthenic crisis — Both PLEX and IVIG are established first-line therapies for acute crises. PLEX achieves faster antibody reduction, while IVIG is logistically simpler.
  2. Guillain-Barré syndrome (GBS) — IVIG at 2 g/kg and PLEX are each supported by randomized controlled trial evidence as equivalent monotherapy options; the landmark 1992 Dutch GBS Study Group trial published in the New England Journal of Medicine demonstrated IVIG non-inferiority to PLEX.
  3. Chronic inflammatory demyelinating polyneuropathy (CIDP) — IVIG holds FDA approval for CIDP, with the PRIMA study and PATH study demonstrating significant reductions in relapse rates with subcutaneous and intravenous formulations.
  4. Neuromyelitis optica spectrum disorder (NMOSD) — PLEX is classified as a Category I ASFA indication for acute attacks; IVIG is less consistently used in this condition.
  5. Autoimmune encephalitis — including anti-NMDA receptor encephalitis, where both therapies serve as first-line immunotherapy before escalation to rituximab or cyclophosphamide.
  6. Multiple sclerosis acute relapse — PLEX is used as a Category II ASFA indication for steroid-refractory relapses.

Decision boundaries

Choosing between PLEX and IVIG involves clinical, logistical, and patient-specific factors structured around four primary considerations:

Speed of response required
PLEX achieves antibody depletion within the first 1 to 2 exchanges and is preferred when rapid reversal of neuromuscular failure or respiratory compromise is the immediate goal. IVIG clinical effect typically peaks at 2 to 4 weeks post-infusion.

Access and infrastructure
PLEX requires specialized apheresis equipment and trained personnel. It is typically available only in hospital settings and carries a higher procedural complexity, including the need for large-bore intravenous or central venous access. IVIG can be administered in outpatient infusion centers and, for maintenance dosing, in home infusion settings.

Contraindications and safety profile
PLEX carries risks associated with fluid shifts, hypotension (occurring in approximately 5 to 10% of procedures according to ASFA guidance), citrate-related hypocalcemia, and line-associated infection. IVIG risks include headache, aseptic meningitis, thromboembolic events, and — critically — hemolysis and renal injury, particularly at high doses. Patients with selective IgA deficiency face anaphylaxis risk with IVIG due to anti-IgA antibodies; IgA levels must be checked before first administration. The FDA requires IVIG product labeling to carry a boxed warning for renal dysfunction, acute renal failure, and thrombotic events.

Concurrent medications
IVIG contains IgG that can interfere with live-virus vaccine immunogenicity for 3 to 11 months following administration, per CDC Advisory Committee on Immunization Practices (ACIP) guidance. PLEX removes recently administered small-molecule drugs and some biologic agents from circulation; dosing of concurrent immunosuppressants must be timed after exchanges.

When neither monotherapy achieves adequate response, combination PLEX followed by IVIG has been used in refractory myasthenic crisis, though evidence for the combination over either agent alone remains limited. Escalation to long-term immunosuppression with agents such as azathioprine, mycophenolate, or rituximab is the standard next step for conditions requiring ongoing immune modulation beyond acute stabilization.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)